Ken Griffin Autolus Therapeutics PLC Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.38 - $4.69 $7,098 - $9,849	-2,100 Reduced 72.41%	800 $2,000
Q2 2024 Aug 14, 2024	SELL	$3.33 - $5.68 $15,651 - $26,696	-4,700 Reduced 61.84%	2,900 $10,000
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $23,177 - $31,347	4,300 Added 130.3%	7,600 $48,000
Q4 2023 Feb 14, 2024	BUY	$2.13 - $6.63 $7,029 - $21,879	3,300 New	3,300 $21,000
Q2 2023 Aug 14, 2023	SELL	$1.64 - $3.21 $491 - $963	-300 Reduced 4.11%	7,000 $16,000
Q1 2023 May 15, 2023	BUY	$1.75 - $2.25 $9,975 - $12,825	5,700 Added 356.25%	7,300 $13,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $2,784 - $5,232	1,600 New	1,600 $3,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.